Overview of Upcoming Financial Results
Verona Pharma plc (NASDAQ: VRNA) is gearing up to release its financial results for the third quarter, concluding on September 30, 2024. The scheduled announcement will take place on November 4, 2024. This event is crucial for investors and stakeholders looking to understand the company’s financial health and strategic direction.
Conference Call Details
On the day of the report, Verona Pharma will host a conference call at 9:00 a.m. EDT (2:00 p.m. GMT). This forum will provide an excellent opportunity for the investment community to glean insights directly from the company's leadership regarding their financial performance and future strategies. Interested participants can join by dialing in on either of the following numbers:
- For callers in the United States: +1-833-816-1396
- For international callers: +1-412-317-0489
Live Webcast Accessibility
For those unable to participate via phone, Verona Pharma will provide a live webcast that can be accessed from the Events and Presentations section on their official website. A recording of the call will be available for playback for up to 90 days following the event, ensuring that interested parties can stay informed at their convenience.
Contact Information for Inquiries
For any additional information about the conference call or the upcoming financial report, interested stakeholders can reach out to:
Verona Pharma plc
Phone: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications
Email: IR@veronapharma.com
Argot Partners
US Investor Inquiries
Phone: +1-212-600-1902
Email: verona@argotpartners.com
Ten Bridge Communications
International / US Media Inquiries
Phone: +1-312-523-5016
Email: tbcverona@tenbridgecommunications.com
About Verona Pharma
Verona Pharma is a forward-thinking biopharmaceutical company dedicated to innovating and commercializing groundbreaking therapies for chronic respiratory diseases. Its flagship product, Ohtuvayre™ (ensifentrine), is significant as it represents the first inhaled therapy that merges both bronchodilator and non-steroidal anti-inflammatory effects in a singular solution. This dual-action mechanism presents a promising option not only for the treatment of Chronic Obstructive Pulmonary Disease (COPD) but also for a variety of other respiratory conditions, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma. The ongoing development work positions Verona Pharma to address critical unmet needs in respiratory healthcare.
For further insights, interested parties can explore more on the company's endeavors by visiting Verona Pharma's website.
Frequently Asked Questions
What is the date for Verona Pharma's Q3 2024 results announcement?
Verona Pharma will announce its Q3 2024 financial results on November 4, 2024.
What time will the conference call take place?
The conference call is scheduled for 9:00 a.m. EDT / 2:00 p.m. GMT.
How can I listen to the conference call?
You can join the conference call by dialing the respective numbers for US and international callers or by accessing the live webcast on their official website.
Who can I contact for more information?
For further information, you can contact Verona Pharma directly at +1-844-341-9901 or via email.
What is Ohtuvayre™?
Ohtuvayre™ (ensifentrine) is Verona Pharma's first commercial product designed to treat COPD by providing both bronchodilation and anti-inflammatory benefits in one inhaled therapy.
